证券代码：300233 证券简称：金城医药 公告编号：2025-042 山东金城医药集团股份有限公司 关于签署权益许可和经销协议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本协议的签署不会对公司本年度财务状况及经营业绩构成重大影响。 2、本次合作不构成关联交易，亦不构成重大资产重组。 一、协议签署情况 山东金城医药集团股份有限公司（以下简称"公司"或"金城医药"）近日与 Theramex HQ UK Limited (以下简称"Theramex")签署了《权益许可和经销协议》 （以下简称"本协议"或"协议"）。双方就用于绝经后妇女雌激素缺乏症状的连 续联合激素替代疗法（HRT）的雌二醇黄体酮软胶囊（以下简称"Bijuva"，为其 商品名）在中国境内的权益许可和经销协议达成合作，金城医药获得该产品在中国 大陆、香港和澳门的独家排他的商业化权益。 本次签署合作协议不涉及关联交易，亦不构成《上市公司重大资产重组管理办 法》规定的重大资产重组。本协议无需提交公司董事会、股东大会审议批准。 二、协议对方介绍 5、履约能力分析：Theramex ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司 关于参加 2025 年山东辖区上市公司投资者网上集体 接待日活动的公告 为进一步加强与投资者的互动交流，山东金城医药集团股份有限公司（以下 简称"公司"）将参加由山东证监局、山东上市公司协会与深圳市全景网络有限 公司联合举办的"2025 年山东辖区上市公司投资者网上集体接待日活动"，现 将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景 路演APP,参与本次互动交流。活动时间为2025年5月15日（周四）15:00-16:30。 届时公司董事会秘书朱晓刚先生、财务总监刘静女士将在线就公司 2024 年度业 绩、公司治理、发展战略、经营状况和可持续发展等投资者关心的问题，与投资 者进行沟通与交流，欢迎广大投资者踊跃参与！ 证券代码：300233 证券简称：金城医药 公告编号：2025-041 特此公告。 2025 年 5 月 12 日 - 1 - 山东金城医药集团股 ...

Market Performance - The Shanghai Composite Index and Shenzhen Component Index experienced declines of 0.30% and 0.69% respectively on May 5, 2025, while the ChiNext Index and STAR Market 50 fell by 0.87% and 1.96% respectively [1] - Among 33 A-share companies in Zibo, 30 saw an increase, 1 remained flat, and 2 declined during the same period [1] Notable Stock Movements - Weiming Pharmaceutical (002581) achieved a remarkable 23.29% increase over five days, leading the gains [1] - Yahua Electronics (301337) and Jincheng Pharmaceutical (300233) also saw significant increases of 17.30% and 11.31% respectively [1] - On May 7, PEEK material concept stocks surged, with Zhongxin Fluorine Materials (002915) hitting the daily limit for the sixth time in nine days, and Kaisheng New Materials (301069) rising by 2.29% with a trading volume of 4.02 billion yuan [1] Company Announcements - Kehui Co., Ltd. announced a share repurchase plan with a budget between 9 million and 16 million yuan, with a maximum repurchase price of 17 yuan per share, aimed at employee stock ownership plans [1] Financial Results - Furuida (600223) reported a revenue of 526 million yuan in its cosmetics segment for Q1 2025, with a gross margin of 61.06% [3] - Qichang Tenda (002408) achieved total revenue of 5.618 billion yuan in Q1 2025, a year-on-year increase of 2.53%, but saw a significant drop in net profit by 83.18% to 5.4007 million yuan [3] - Xinhua Medical (600587) reported a total revenue of 2.308 billion yuan, down 8.74% year-on-year, with a net profit decline of 23.97% to 160 million yuan [3] - Bohui Paper (600966) reported a total revenue of 4.564 billion yuan, a 3.77% increase year-on-year, but a net profit decline of 46.91% to 53.3737 million yuan [3] Market Capitalization - In terms of market capitalization, Yingke Medical (300677) led with 14.708 billion yuan, followed closely by Shandong Pharmaceutical Glass (600529) at 14.626 billion yuan, and Qichang Tenda (002408) at 12.963 billion yuan [4]

Group 1 - The genetically modified (GM) concept sector declined by 1.12%, ranking among the top declines in concept sectors, with leading decliners including Fengle Seed Industry, Qianyuan High-Tech, and Wanxiang DeNong [1][2] - Among the GM concept stocks, only four experienced price increases, with Ba Tian Co., Qian Qian Bio, and Top Cloud Agriculture rising by 2.16%, 1.92%, and 1.85% respectively [1][2] - The GM concept sector saw a net outflow of 123 million yuan from main funds today, with 11 stocks experiencing net outflows, and six stocks seeing outflows exceeding 10 million yuan [2] Group 2 - The stock with the highest net outflow was Qianyuan High-Tech, with a net outflow of 28.98 million yuan, followed by Fengle Seed Industry, Dabeinong, and Shennong Seed Industry with net outflows of 25.65 million yuan, 22.57 million yuan, and 18.05 million yuan respectively [2][3] - The stocks with the highest net inflows included Top Cloud Agriculture, Longping High-Tech, and Ba Tian Co., with net inflows of 7.65 million yuan, 7.01 million yuan, and 2.32 million yuan respectively [3]

证券代码：300233 证券简称：金城医药 公告编号：2025-040 山东金城医药集团股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、公司 2024 年年度权益分派方案已获 2025 年 4 月 22 日召开的 2024 年年度股 东大会审议通过，具体内容为：以扣除公司回购专户中已回购股份后的总股本 379,331,587 股为基数（公司总股本 383,874,587 股，扣除公司回购专户股份数量 4,543,000 股），向股权登记日登记在册的全体股东每 10 股派发现金红利人民币 1.5 元（含税），共计派发现金红利人民币 56,899,738.05 元（含税）。本次利润分配不 送红股，不以资本公积金转增股本。 2、因公司回购专户的股份不享有参与利润分配的权利，公司本次实际派发现金 分红总额=（383,874,587 股-4,543,000 股）÷10×1.5 元/股=56,899,738.05 元。 本次权益分派实施后计算除权除息价格时，按总股本（含回购股份，下同）计算的每 10 股派息（ ...

Financial Performance - The company's revenue for Q1 2025 was ¥721,919,205.16, a decrease of 22.52% compared to ¥931,696,552.76 in the same period last year[5]. - Net profit attributable to shareholders was ¥35,054,760.33, down 57.75% from ¥82,971,349.76 year-on-year[5]. - Basic earnings per share decreased by 59.09% to ¥0.09 from ¥0.22 in the same period last year[5]. - Net profit for the current period is ¥36,298,903.66, a decline of 59.3% compared to ¥89,158,928.05 in the previous period[23]. - Basic and diluted earnings per share are both ¥0.09, down from ¥0.22 in the previous period[24]. Cash Flow - The net cash flow from operating activities was -¥8,565,391.95, a decline of 120.70% compared to ¥41,373,196.64 in the previous year[5]. - Cash flow from operating activities shows a net outflow of ¥8,565,391.95, compared to a net inflow of ¥41,373,196.64 in the previous period[25]. - The net cash flow from financing activities was -¥65,461,298.33, a decline of 354.21% compared to a net inflow of ¥25,751,266.86 in the previous year[14]. - Cash and cash equivalents decreased to ¥853,676,725.38 from ¥917,670,953.09[17]. - Cash and cash equivalents at the end of the period amount to ¥796,398,844.56, down from ¥921,001,178.30 at the end of the previous period[26]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,471,384,233.67, down 2.38% from ¥5,604,990,741.71 at the end of the previous year[5]. - Total current assets amount to ¥2,184,257,009.16, a decrease from ¥2,258,285,131.73 at the beginning of the period[18]. - Total liabilities decreased to ¥1,657,956,535.57 from ¥1,772,836,587.70[19]. - Total assets and equity decreased to ¥5,471,384,233.67 and ¥3,813,427,698.10 respectively, from ¥5,604,990,741.71 and ¥3,832,154,154.01 in the previous period[20]. - The company has a total equity of ¥3,813,427,698.10, unchanged from the previous period[19]. Operational Metrics - The decline in revenue was primarily due to a decrease in the prices of pharmaceutical intermediates and the impact of national centralized procurement on sales volume and prices of certain products[9]. - Sales expenses decreased by 56.48% to ¥74,794,902.94, attributed to reduced market promotion activities due to centralized procurement[13]. - Total operating costs for the current period are ¥682,091,200.85, down 17.3% from ¥824,597,996.18 in the previous period[21]. - The company reported a significant increase in accounts receivable by 144.70% to ¥51,960,111.27 due to increased issuance of pledged notes[12]. - The company experienced a significant increase in credit impairment losses, totaling ¥7,015,544.06, compared to ¥2,270,345.38 in the previous period[23]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 33,604[16]. - The largest shareholder, Zibo Jincheng Industrial Investment Co., Ltd., holds 20.46% of shares, totaling 78,552,154 shares, with 17,588,900 shares pledged[16]. Inventory and Expenditures - The company’s inventory stands at ¥596,359,058.41, slightly down from ¥598,863,558.41[17]. - The company has ongoing development expenditures of ¥252,798,405.62, up from ¥240,729,227.18[18]. Future Outlook - The company plans to implement new accounting standards starting from 2025, which may impact future financial reporting[27].

Group 1 - The core point of the article indicates that Jincheng Pharmaceutical (300233) reported a revenue of 722 million yuan in the first quarter of 2025, representing a year-on-year decline of 22.52% [1] - The net profit for the same period was 35.05 million yuan, which reflects a significant year-on-year decrease of 57.75% [1]

证券代码：300233 证券简称：金城医药 公告编号：2025-038 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会不存在增加、变更、否决议案的情况； 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开情况 本次会议的召集、召开符合《中华人民共和国公司法》《上市公司股东会规 则》《深圳证券交易所创业板股票上市规则》等有关法律、行政法规、部门规章、 规范性文件和《山东金城医药集团股份有限公司章程》的有关规定。 二、会议出席情况 山东金城医药集团股份有限公司 （一）股东总体出席情况 通过现场和网络投票的股东 286 人，代表股份 91,480,854 股，占公司有表 决权股份总数的 24.1163％。 其中：通过现场投票的股东 7 人，代表股份 80,180,154 股，占公司有表决 权股份总数的 21.1372％。 通过网络投票的股东 279 人，代表股份 11,300,700 股，占公司有表决权股 份总数的 2.9791％。 (二）中小股东出席的总体情况 1、召开时间：2025 ...

北京市中伦（青岛）律师事务所 关于山东金城医药集团股份有限公司 2024 年年度股东大会的 法律意见书 二〇二五年四月 法律意见书 致：山东金城医药集团股份有限公司 北京市中伦（青岛）律师事务所（以下简称"本所"）接受山东金城医药集 团股份有限公司（以下简称"公司"）的委托，根据本法律意见书出具日前已经 发生或存在的事实和《中华人民共和国公司法》（以下简称《公司法》）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》《律师事务 所从事证券法律业务管理办法》《律师事务所证券法律业务执业规则（试行）》等 中华人民共和国（以下简称"中国"，为本法律意见书之目的，不包括香港特别 行政区、澳门特别行政区和台湾地区）现行有效的法律、法规和规范性文件以及 《山东金城医药集团股份有限公司章程》（以下简称"《公司章程》"）、《山东金 城医药集团股份有限公司股东大会议事规则》（以下简称"《股东大会议事规则》"） 等有关规定，指派律师出席公司于 2025 年 4 月 22 日召开的 2024 年年度股东大 会（以下简称"本次股东大会"），并就本次股东大会的相关事项出具本法律意 见书。 为出具本法律意见书 ...

山东金城医药集团股份有限公司（以下简称"公司"）全资子公司上海金城素智 药业有限公司（以下简称"金城素智"）于近日收到由上海市科学技术委员会、上海 市财政局、国家税务总局上海市税务局联合颁发的《高新技术企业证书》，发证日期： 2024年12月26日，证书编号：GR202431002776，有效期三年。 本次系金城素智在原《高新技术企业证书》有效期满后进行的重新认定。根据国 家有关规定，金城素智自高新技术企业认定后连续三年内（2024年至2026年）可继续 享受国家关于高新技术企业的税收优惠政策，即按15%的税率缴纳企业所得税。 本次金城素智通过高新技术企业重新认定不会影响公司2024年度的经营业绩。 特此公告。 山东金城医药集团股份有限公司董事会 山东金城医药集团股份有限公司 关于子公司通过高新技术企业重新认定的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 2025 年 4 月 21 日 证券代码：300233 证券简称：金城医药 公告编号：2025-037 ...